Key Highlights
- On March 25, Chief Global Commercialization Officer Anthony Mancini offloaded 26,552 shares valued at approximately $3.5M through a pre-arranged 10b5-1 trading plan
- The stock started trading at $94.29, reflecting a 1.3% decline, within its annual trading band of $29.17 to $124.49
- Truist Financial issued a strong-buy upgrade on March 26, aligning with bullish calls from Jefferies, Evercore, UBS, and Wedbush
- Company insiders have divested approximately 149,592 shares totaling roughly $15M over the last three months, while institutional holders control 94.34%
- Fourth quarter 2025 results showed a loss of $1.86 per share, exceeding the expected loss of $1.56, primarily due to elevated R&D and operational spending
Shares of Revolution Medicines (RVMD) began Wednesday’s session, March 26, at $94.29, representing a 1.3% pullback.
Revolution Medicines, Inc., RVMD
The company’s Chief Global Commercialization Officer, Anthony Mancini, executed a sale of 26,552 shares on March 25, generating proceeds of approximately $3.5 million. The share prices during these transactions varied between $93.22 and $97.21.
These sales occurred through a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such programs allow executives to schedule trades in advance, suggesting these transactions don’t necessarily reflect current views on the company’s prospects.
Concurrently, Mancini exercised stock options to purchase 37,450 shares at $33.62 each, amounting to roughly $1.26 million. Following these activities, his direct holdings include 54,400 common shares plus 54,400 restricted stock units.
Mancini’s activity follows a pattern of recent insider transactions. Mark A. Goldsmith, another company insider, disposed of 12,871 shares on March 17 at an average price of $99.48, generating proceeds exceeding $1.28 million. That same day, CFO Jack Anders sold 2,753 shares at the identical price point, collecting approximately $274,000.
Combined insider selling over the previous 90 days totals roughly 149,592 shares valued at $15 million. Company insiders collectively maintain 8.20% ownership.
Wall Street Upgrades Signal Confidence
Contrary to the insider selling pattern, Wall Street analysts maintain predominantly optimistic views. Truist Financial elevated RVMD to a strong-buy rating on March 26.
Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a buy rating on March 16. UBS similarly initiated coverage with a buy rating on February 27.
Weiss Ratings represents the sole bearish voice, maintaining a sell (d-) rating. MarketBeat’s aggregated consensus indicates a “Buy” recommendation with a consensus price target of $78.94—notably beneath current market levels.
Individual firm targets paint a more optimistic picture. Piper Sandler established a $120 target (Overweight rating), Wells Fargo set theirs at $144, while Needham positioned their target at $145 alongside a Buy recommendation.
Institutional Capital Flows In Despite Quarterly Shortfall
Institutional investment activity has surged recently. Norges Bank established a fresh position valued at approximately $195.6 million during Q4. Avoro Capital initiated a position worth roughly $172.8 million. UBS expanded its holdings by 183.6%, reaching 3,087,937 shares valued near $246 million. Polar Capital accelerated its position by 321.2%, now controlling over 2 million shares.
Collectively, institutional investors command 94.34% of RVMD ownership.
This institutional enthusiasm persists despite the company’s Q4 2025 earnings disappointment. Revolution Medicines posted a per-share loss of $1.86, falling short of the consensus forecast of -$1.56 by $0.30. Management attributed the variance to research and development expenditures and selling, general, and administrative costs exceeding projections.
The revenue picture remained solid—the company closed the quarter with $2.03 billion in cash and investments, partially supported by an agreement with Royalty Pharma. Wall Street projects a full-year fiscal 2026 loss of $3.49 per share.
RVMD currently trades with a 50-day moving average of $101.53 and a 200-day moving average of $78.24. The company’s market capitalization stands at $18.69 billion.
The stock has delivered remarkable returns, climbing 145% over the trailing twelve months and gaining 112% during the past six months.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
